Fillers, without the filler.

Midface volumization is where modern filler earned its reputation. In the Voluma pivotal RCT (235 treated vs 47 controls), 85.6% improved at least one point on a validated volume-deficit scale at 6 months, and 79% still rated themselves improved at 2 years — the longest supported duration of any filler area.

Restoring the cheek also softens what's below it: nasolabial folds and jowl shadows partially improve when midface support returns, which is why good injectors often start here rather than at the fold itself.

Typical treatment: 2–4 ml across both cheeks, occasionally with a touch-up. Bruising and swelling settle within days.

Lips have unusually good data because two modern products ran head-to-head pivotal programs: Volbella (225 adults, responder rate >60% at 12 months) and Restylane Kysse (~280 subjects, 48 weeks, similar fullness with ~20% less product). Perioral "smoker's lines" improved in about two-thirds of patients in the same trials.

The honest caveat: pooled safety data show swelling and lumps are significantly more frequent in lips than in the nasolabial folds — plan a social buffer of several days.

Typical treatment: up to 1 ml per session (both pivotal trials capped there). Natural results come from respecting lip proportions, not maximizing volume; "filler moustache" migration is largely a repeat-overfill phenomenon.

Every major filler earned its US approval in the nasolabial fold, so this area has the deepest RCT base in aesthetics — head-to-head trials, a 2024 network meta-analysis, and validated wrinkle scales. All modern HA products beat the old collagen comparators and are broadly interchangeable in trials.

Two practical notes: deep folds usually reflect midface deflation, so treating the cheek first often halves what the fold needs. And this is among the safer zones — but the nearby facial artery still demands a trained injector.

Chin augmentation crossed from "off-label habit" to evidence-based in 2020, when Voluma won a dedicated FDA approval on a 221-patient randomized pivotal trial with 1-year follow-up; individual adverse events each ran under 5% and resolved within weeks.

A modest chin correction changes profile harmony more than most people expect — it's frequently paired with jawline work. Firm, high-lift gels are used here; results typically hold about a year.

Efficacy first: a 2023 meta-analysis pooled tear-trough studies and found 91% overall satisfaction — but from small uncontrolled series. The randomised data came later: in the pivotal trial behind Restylane Eyelight's 2023 US approval, 87% of treated patients improved at three months against 18% of untreated controls (Biesman 2024), and Juvéderm Volbella XC holds the same US approval; for most other products the area is off-label.

Safety is what makes this area special, in the wrong way. A systematic review of delayed tear-trough complications found swelling (42% of delayed cases), nodules (25%), migration and discoloration appearing at a mean of 17 months after injection; the thin eyelid skin also shows the blue-grey Tyndall effect when gel sits too superficially, and long-term studies document late puffiness from persistent filler.

If you do it: small volumes of a soft, low-swelling gel, by an oculoplastic or highly experienced medical injector — and accept that "no" (or fat repositioning surgery) is sometimes the better answer for deep hollows.

Jawline filler became officially evidence-based in 2022 when Juvéderm Volux was approved for jawline definition on a randomized controlled study. One pivotal program and a shorter track record keep it a notch below chin and cheeks — and it cannot fix genuine jowling from skin laxity, only sharpen the bony line.

Volume needs are larger here (often 2–4 ml), which makes injector judgment about whether you're a good candidate more valuable than the syringe count.

Marionette lines (mouth-corner to chin) respond to flexible fillers designed for mobile areas — Restylane Refyne/Defyne carry FDA approval for the nasolabial folds (marketed as "laugh lines"), not for this area, and perioral rhytids improved in ~65% of patients in the Volbella pivotal trial. Dedicated marionette-only RCTs are scarce; most evidence sits inside multi-area lower-face programs.

Downturned mouth corners often need a combination approach (a little support at the corner, chin stabilization, sometimes botulinum toxin to the depressor muscle) rather than more gel in the line itself.

Hands age loudly — veins and tendons surface as the fat pad deflates. Restylane Lyft is FDA-approved for dorsal hands on a randomized, evaluator-blinded split-hand study of 89 patients: clinically meaningful volume correction to 6 months, with predominantly mild, temporary swelling and tenderness (including brief impaired hand function).

It pairs naturally with IPL or pigment lasers for sun spots — volume fixes the deflation, light fixes the discoloration.

A 2024 systematic review pooling 9,657 liquid-rhinoplasty patients reported 99.1% satisfaction — camouflaging a hump or lifting a tip with fractions of a millilitre genuinely works. The same pooled analysis is the reason to pause: serious vascular complications — blindness, skin necrosis, stroke — occurred in 0.27%, roughly 1 in 370, the worst serious-event profile of any filler area, and the nose is the top site (40.6%) in the world filler-blindness literature.

The nasal arteries connect directly toward the eye's blood supply, and previously operated noses are riskier still. If you choose it anyway: an expert medical injector, tiny volumes, cannula technique, never soon after a surgical rhinoplasty.

Caveat: satisfaction data come from uncontrolled case series; there is no pivotal RCT, and the use is off-label.

Neck rings and chest wrinkles respond modestly to dilute HA "skin booster" techniques: a 2025 open-label study (81 volunteers treated on the face, neck or chest, 3 sessions) found significant hydration, elasticity, and wrinkle-depth improvements over 6 months with mild transient side effects. A open-label Skinboosters study in the décolletage is registered but unreported — until it lands, this stays an "emerging" indication with real but small, uncontrolled support.